FDA Week

Stakeholders See Little Action From Gottlieb On Off-Label, Most Aren't Worried

September 07, 2017
Stakeholders on both sides of the off-label debate have seen little indication as to where Scott Gottlieb will take the agency on the contentious issue, but neither side appears overly troubled by the lack of action on the issue in his first 100 days, and some call it a smart approach. Top industry stakeholders have yet to meet with Gottlieb on the issue, the groups tell Inside Health Policy . While some stakeholders predict Gottlieb's appointment of a former industry...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.